Mydecine Innovations Group Inc. (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) CEO Josh Bartch tells Proactive its R&D team has made groundbreaking advances in psilocybin research with the discovery of over 40 compounds with pharmacological potential in mushrooms.
Bartch says what's more, the group has received approval from Health Canada to “significantly expand” its cultivation capabilities at its facility, at Applied Pharmaceutical Innovation in Canada.